Clinical features of oral chemotherapy: results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK.
AffiliationUniversity of Manchester, School of Nursing, Midwifery and Social Work, University Place, Manchester M13 9PL, UK. sarah.Brearley@manchester.ac.uk
MetadataShow full item record
AbstractThe aim was to describe the clinical sequelae of patients treated with capecitabine in terms of adverse events, treatment modifications and therapy cessation throughout the treatment trajectory. A total of 1232 toxicity assessments were undertaken on colorectal and breast cancer patients receiving palliative and adjuvant treatment prior to treatment and at days 7, 14 and 21 for six cycles of chemotherapy. Most common adverse events were diarrhoea, nausea, palmar-plantar erythrodysesthesia (PPE), fatigue and pain which were experienced by over 80% of subjects. Grades 2 and 3 adverse events were common (n= 916 and n= 113) but their development into grade 4 was uncommon (n= 2). There was a downward trend in the percentage incidence of toxicity; however, PPE increased. Almost 60% of subjects completed six cycles, or planned treatment. Some 40% of subjects commenced treatment on a dose reduction (<1250 mg/m(2)), and this increased to 70% at cycle 6. In total, 2.8-11.6% of subjects experienced toxicity-related treatment deferrals. While adverse events are common with capecitabine the lack of grade 4 adverse events support the efficacy of current clinical management strategies. The deferral and dose reduction data indicate that cycles 1 and 2 are important and require careful management and clinical interventions in order to prevent high-grade adverse events.
CitationClinical features of oral chemotherapy: results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK. 2010, 19 (4):425-33 Eur J Cancer Care
JournalEuropean Journal of Cancer Care
- Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
- Authors: Rossi D, Alessandroni P, Catalano V, Giordani P, Fedeli SL, Fedeli A, Baldelli AM, Casadei V, Ceccolini M, Catalano G
- Issue date: 2007 Dec
- Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
- Authors: Chalermchai T, Tantiphlachiva K, Suwanrusme H, Voravud N, Sriuranpong V
- Issue date: 2010 Sep
- Capecitabine non-adherence: exploration of magnitude, nature and contributing factors.
- Authors: Bhattacharya D, Easthall C, Willoughby KA, Small M, Watson S
- Issue date: 2012 Sep
- Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature.
- Authors: Hennessy BT, Gauthier AM, Michaud LB, Hortobagyi G, Valero V
- Issue date: 2005 Aug
- Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
- Authors: Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, Karabelis A, Tsavaris N
- Issue date: 2008 Jan